Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

E. John Orav, Ph.D.

Co-Author

This page shows the publications co-authored by E. Orav and Steven Colan.
Connection Strength

1.867
  1. Evolution of hypertrophic cardiomyopathy in sarcomere mutation carriers. Heart. 2016 Nov 15; 102(22):1805-1812.
    View in: PubMed
    Score: 0.174
  2. Cardiac effects of antiretroviral therapy in HIV-negative infants born to HIV-positive mothers: NHLBI CHAART-1 (National Heart, Lung, and Blood Institute Cardiovascular Status of HAART Therapy in HIV-Exposed Infants and Children cohort study). J Am Coll Cardiol. 2011 Jan 04; 57(1):76-85.
    View in: PubMed
    Score: 0.118
  3. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol. 2010 Oct; 11(10):950-61.
    View in: PubMed
    Score: 0.115
  4. Gender differences in long-term dexrazoxane cardioprotection in doxorubicin-treated children with acute lymphoblastic leukemia. J Clin Oncol. 2009 May 20; 27(15_suppl):10005.
    View in: PubMed
    Score: 0.105
  5. Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children: findings from the Pediatric Cardiomyopathy Registry. Circulation. 2007 Feb 13; 115(6):773-81.
    View in: PubMed
    Score: 0.089
  6. The incidence of pediatric cardiomyopathy in two regions of the United States. N Engl J Med. 2003 Apr 24; 348(17):1647-55.
    View in: PubMed
    Score: 0.069
  7. Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial. Nat Med. 2021 10; 27(10):1818-1824.
    View in: PubMed
    Score: 0.062
  8. Reliability of multicenter pediatric echocardiographic measurements of left ventricular structure and function: the prospective P(2)C(2) HIV study. Circulation. 2001 Jul 17; 104(3):310-6.
    View in: PubMed
    Score: 0.061
  9. Cardiac dysfunction and mortality in HIV-infected children: The Prospective P2C2 HIV Multicenter Study. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection (P2C2 HIV) Study Group. Circulation. 2000 Sep 26; 102(13):1542-8.
    View in: PubMed
    Score: 0.058
  10. Absence of cardiac toxicity of zidovudine in infants. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection Study Group. N Engl J Med. 2000 Sep 14; 343(11):759-66.
    View in: PubMed
    Score: 0.058
  11. Left ventricular diastolic dysfunction in HIV-uninfected infants exposed in utero to antiretroviral therapy. AIDS. 2020 03 15; 34(4):529-537.
    View in: PubMed
    Score: 0.056
  12. Baseline Characteristics of the VANISH Cohort. Circ Heart Fail. 2019 12; 12(12):e006231.
    View in: PubMed
    Score: 0.055
  13. Left ventricular structure and function in children infected with human immunodeficiency virus: the prospective P2C2 HIV Multicenter Study. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection (P2C2 HIV) Study Group. Circulation. 1998 Apr 07; 97(13):1246-56.
    View in: PubMed
    Score: 0.049
  14. Biomarkers of cardiovascular stress and fibrosis in preclinical hypertrophic cardiomyopathy. Open Heart. 2017; 4(2):e000615.
    View in: PubMed
    Score: 0.047
  15. Cardiac Effects of Highly Active Antiretroviral Therapy in Perinatally HIV-Infected Children: The CHAART-2 Study. J Am Coll Cardiol. 2017 Oct 31; 70(18):2240-2247.
    View in: PubMed
    Score: 0.047
  16. The Burden of Early Phenotypes and the Influence of Wall Thickness in Hypertrophic Cardiomyopathy Mutation Carriers: Findings From the HCMNet Study. JAMA Cardiol. 2017 04 01; 2(4):419-428.
    View in: PubMed
    Score: 0.045
  17. The Design of the Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Trial. Am Heart J. 2017 May; 187:145-155.
    View in: PubMed
    Score: 0.045
  18. Health-Related Quality of Life and Functional Status Are Associated with Cardiac Status and Clinical Outcome in Children with Cardiomyopathy. J Pediatr. 2016 Mar; 170:173-80.e1-4.
    View in: PubMed
    Score: 0.041
  19. Immunoglobulins and left ventricular structure and function in pediatric HIV infection. Circulation. 1995 Oct 15; 92(8):2220-5.
    View in: PubMed
    Score: 0.041
  20. Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med. 1995 06 29; 332(26):1738-43.
    View in: PubMed
    Score: 0.040
  21. Diltiazem treatment for pre-clinical hypertrophic cardiomyopathy sarcomere mutation carriers: a pilot randomized trial to modify disease expression. JACC Heart Fail. 2015 Feb; 3(2):180-8.
    View in: PubMed
    Score: 0.038
  22. Limitations of fractional shortening as an index of contractility in pediatric patients infected with human immunodeficiency virus. J Pediatr. 1994 Oct; 125(4):563-70.
    View in: PubMed
    Score: 0.038
  23. Risk stratification at diagnosis for children with hypertrophic cardiomyopathy: an analysis of data from the Pediatric Cardiomyopathy Registry. Lancet. 2013 Dec 07; 382(9908):1889-97.
    View in: PubMed
    Score: 0.035
  24. Individual pulmonary vein size and survival in infants with totally anomalous pulmonary venous connection. J Am Coll Cardiol. 1993 Jul; 22(1):201-6.
    View in: PubMed
    Score: 0.035
  25. Comparison of echocardiographic and cardiac magnetic resonance imaging in hypertrophic cardiomyopathy sarcomere mutation carriers without left ventricular hypertrophy. Circ Cardiovasc Genet. 2013 Jun; 6(3):230-7.
    View in: PubMed
    Score: 0.035
  26. Cardiac structure and function in children with human immunodeficiency virus infection treated with zidovudine. N Engl J Med. 1992 Oct 29; 327(18):1260-5.
    View in: PubMed
    Score: 0.033
  27. Subtle abnormalities in contractile function are an early manifestation of sarcomere mutations in dilated cardiomyopathy. Circ Cardiovasc Genet. 2012 Oct 01; 5(5):503-10.
    View in: PubMed
    Score: 0.033
  28. Competing risks for death and cardiac transplantation in children with dilated cardiomyopathy: results from the pediatric cardiomyopathy registry. Circulation. 2011 Aug 16; 124(7):814-23.
    View in: PubMed
    Score: 0.031
  29. The pediatric cardiomyopathy registry and heart failure: key results from the first 15 years. Heart Fail Clin. 2010 Oct; 6(4):401-13, vii.
    View in: PubMed
    Score: 0.029
  30. Treating children with idiopathic dilated cardiomyopathy (from the Pediatric Cardiomyopathy Registry). Am J Cardiol. 2009 Jul 15; 104(2):281-6.
    View in: PubMed
    Score: 0.026
  31. Characteristics and outcomes of cardiomyopathy in children with Duchenne or Becker muscular dystrophy: a comparative study from the Pediatric Cardiomyopathy Registry. Am Heart J. 2008 Jun; 155(6):998-1005.
    View in: PubMed
    Score: 0.024
  32. Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA. 2006 Oct 18; 296(15):1867-76.
    View in: PubMed
    Score: 0.022
  33. Factors associated with establishing a causal diagnosis for children with cardiomyopathy. Pediatrics. 2006 Oct; 118(4):1519-31.
    View in: PubMed
    Score: 0.022
  34. Mild dilated cardiomyopathy and increased left ventricular mass predict mortality: the prospective P2C2 HIV Multicenter Study. Am Heart J. 2005 Sep; 150(3):439-47.
    View in: PubMed
    Score: 0.020
  35. Cardiovascular outcomes of pediatric seroreverters perinatally exposed to HAART: design of a longitudinal clinical study. Cardiovasc Toxicol. 2004; 4(2):187-97.
    View in: PubMed
    Score: 0.018
  36. Cardiovascular status of infants and children of women infected with HIV-1 (P(2)C(2) HIV): a cohort study. Lancet. 2002 Aug 03; 360(9330):368-73.
    View in: PubMed
    Score: 0.016
  37. Design and implementation of the North American Pediatric Cardiomyopathy Registry. Am Heart J. 2000 Feb; 139(2 Pt 3):S86-95.
    View in: PubMed
    Score: 0.014
  38. Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia. J Clin Oncol. 1998 Feb; 16(2):545-50.
    View in: PubMed
    Score: 0.012
  39. Nutritional status and cardiac mass and function in children infected with the human immunodeficiency virus. Am J Clin Nutr. 1997 Sep; 66(3):660-4.
    View in: PubMed
    Score: 0.012
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.